Table 1.
Overall (n = 1303) | Recurrence (107) | No recurrence (1196) | OR (95%CI) | P-value | |
Gender | |||||
Male | 681 (52.3) | 65 (60.7) | 616 (51.5) | ||
Female | 622 (47.7) | 42 (39.3) | 580 (48.5) | 0.686 (0.458, 1.028) | 0.067 |
Age (yr) | |||||
Mean (SD) | 55.77 (13.696) | 55.76 (0.390) | 55.83 (1.538) | 1.000 (0.986, 1.015) | 0.276 |
Tumor location | |||||
Gastric | 873 (67.0) | 38 (35.5) | 835 (69.8) | ||
Non-gastric | 430 (33.0) | 69 (64.5) | 361 (30.2) | 4.200 (2.774, 6.359) | < 0.05 |
Follow-up period (mo) | |||||
Mean (SD) | 64.91 (35.793) | 75.36 (4.608) | 63.98 (0.995) | 1.008 (1.003, 1.013) | < 0.05 |
Tumor size | |||||
Mean (SD) | 5.14 (4.862) | 9.01 (0.663) | 4.80 (0.130) | 1.128 (1.092, 1.165) | < 0.05 |
≤ 5 cm | 775 (59.5) | 28 (26.2) | 747 (62.5) | ||
> 5 cm | 528 (40.5) | 79 (73.8) | 449 (37.5) | 4.694 (3.003, 7.337) | < 0.05 |
Mitotic index | |||||
≤ 5/50 HPFs | 877 (67.3) | 44 (41.1) | 833 (69.6) | ||
> 5/50 HPFs | 426 (32.7) | 63 (58.9) | 363 (30.4) | 3.286 (2.193, 4.923) | < 0.05 |
Tumor rupture | |||||
Yes | 34 (2.6) | 27 (25.2) | 7 (0.6) | 57.327 (24.220, 135.685) | |
No | 1269 (97.4) | 80 (74.8) | 1189 (99.4) | < 0.05 | |
Modified NIH | |||||
Very low risk | 347 (26.6) | 14 (13.10) | 333 (27.80) | 0.182 (0.101, 0.329) | < 0.05 |
Low risk | 394 (30.2) | 10 (9.30) | 384 (32.10) | 0.113 (0.057, 0.222) | < 0.05 |
Intermediate risk | 162 (12.4) | 8 (7.50) | 154 (12.90) | 0.225 (0.106, 0.478) | < 0.05 |
High risk | 400 (30.7) | 75 (70.10) | 325 (27.20) | ||
AFIP criteria | |||||
Very low risk | 619 (47.5) | 15 (14.00) | 604 (50.50) | 0.081 (0.045, 0.146) | < 0.05 |
Low risk | 250 (19.2) | 16 (15.00) | 234 (19.60) | 0.224 (0.125, 0.401) | < 0.05 |
Intermediate risk | 173 (13.3) | 15 (14.00) | 158 (13.20) | 0.311 (0.170, 0.568) | < 0.05 |
High risk | 261 (20.0) | 61 (57.00) | 200 (16.70) |
OR: Odds ratio; CI: Confidence interval; SD: Standard deviation; HPF: High-power field; AFIP: Armed Forces Institute of Pathology; NIH: National Institutes of Health.